Randomized Phase II Study of Consecutive-Day versus Alternate-Day Treatment with S-1 as Second-Line Chemotherapy in Advanced Pancreatic Cancer

Second Line ◽

Randomized Phase Ii ◽

FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-012-1875-1 ◽

2012 ◽

Vol 69 (6) ◽

pp. 1641-1645 ◽

Cited By ~ 41

Author(s):

Alberto Zaniboni ◽

Enrico Aitini ◽

Sandro Barni ◽

Daris Ferrari ◽

Stefano Cascinu ◽

...

Keyword(s):

Pancreatic Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Second Line ◽

Multicenter Phase ◽

A randomized phase II study of raltitrexed and gefitinib versus raltitrexed alone as second line chemotherapy in patients with colorectal cancer. (1839IL/0143)

Investigational New Drugs ◽

10.1007/s10637-010-9400-z ◽

2010 ◽

Vol 29 (5) ◽

pp. 1038-1044 ◽

Cited By ~ 9

Author(s):

José María Viéitez ◽

Manuel Valladares ◽

Ignacio Peláez ◽

Luis de Sande González ◽

Jesús García-Foncillas ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Second Line ◽

Randomized Phase Ii ◽

Phase II study of palliative S-1 in combination with cisplatin as second-line chemotherapy for gemcitabine-refractory pancreatic cancer patients

Oncology Letters ◽

10.3892/ol.2012.637 ◽

2012 ◽

Vol 3 (6) ◽

pp. 1314-1318 ◽

Cited By ~ 5

Author(s):

HYUN JUNG KIM ◽

JINA YUN ◽

HAN JO KIM ◽

KYOUNG HA KIM ◽

SE HYUNG KIM ◽

...

Keyword(s):

Pancreatic Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

Second Line ◽

Gemcitabine Refractory ◽

2300 A multicenter randomized phase II study of docetaxel vs. docetaxel plus cisplatin vs. docetaxel plus S-1 as second-line chemotherapy in metastatic gastric cancer patients who had progressed after cisplatin plus either S-1 or capecitabine

European Journal of Cancer ◽

10.1016/s0959-8049(16)31216-3 ◽

2015 ◽

Vol 51 ◽

pp. S432 ◽

Cited By ~ 1

Author(s):

B. Kim ◽

K.W. Lee ◽

M.J. Kim ◽

H.S. Han ◽

Y.L. Park ◽

...

Keyword(s):

Gastric Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Gastric Cancer ◽

Second Line ◽

Randomized Phase Ii ◽

Gastric Cancer Patients ◽

Role of second-line chemotherapy in advanced pancreatic cancer and its influence on phase II/III study results

Annals of Oncology ◽

10.1093/annonc/mdt296 ◽

2013 ◽

Vol 24 (9) ◽

pp. 2462-2463

Author(s):

M. Teo ◽

R.S. McDermott

Keyword(s):

Pancreatic Cancer ◽

Phase Ii ◽

Second Line ◽

Study Results ◽

Randomized phase II study of second-line chemotherapy with the best available 5-fluorouracil regimen versus weekly administration of paclitaxel in far advanced gastric cancer with severe peritoneal metastases refractory to 5-fluorouracil-containing regimens (JCOG0407)

Gastric Cancer ◽

10.1007/s10120-015-0542-8 ◽

2015 ◽

Vol 19 (3) ◽

pp. 902-910 ◽

Cited By ~ 26

Author(s):

Tomohiro Nishina ◽

◽

Narikazu Boku ◽

Masahiro Gotoh ◽

Yasuhiro Shimada ◽

...

Keyword(s):

Gastric Cancer ◽

Advanced Gastric Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Peritoneal Metastases ◽

Second Line ◽

Weekly Administration ◽

Randomized Phase Ii ◽

Multicenter Randomized Phase II Study of Weekly Docetaxel Alone Versus Weekly Docetaxel Plus Oxaliplatin as a Second-Line Chemotherapy in Patients with Advanced Gastric Cancer: Preliminary Response and Safety Results

Annals of Oncology ◽

10.1016/s0923-7534(20)31969-4 ◽

2012 ◽

Vol 23 ◽

pp. xi20

Author(s):

J.Y. Kim ◽

Y.R. Do ◽

K.U. Park ◽

H.-M. Ryoo ◽

S.H. Bae ◽

...

Keyword(s):

Gastric Cancer ◽

Advanced Gastric Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Second Line ◽

Weekly Docetaxel ◽

Randomized Phase Ii ◽

Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial

Annals of Oncology ◽

10.1093/annonc/mdl463 ◽

2007 ◽

Vol 18 (4) ◽

pp. 745-751 ◽

Cited By ~ 46

Author(s):

S. Boeck ◽

K. Weigang-Köhler ◽

M. Fuchs ◽

E. Kettner ◽

D. Quietzsch ◽

...

Keyword(s):

Pancreatic Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Second Line ◽

Multicenter Phase ◽

A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer

BMC Cancer ◽

10.1186/1471-2407-14-937 ◽

2014 ◽

Vol 14 (1) ◽

Cited By ~ 3

Author(s):

Yun Wang ◽

Jørn Herrstedt ◽

Hanne Havsteen ◽

Rene DePoint Christensen ◽

Mansoor Raza Mirza ◽

...

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Phase Ii Study ◽

Second Line ◽

Fallopian Tube Cancer ◽

Platinum Sensitive ◽

Randomized Phase Ii ◽

First Relapse ◽

A randomized phase II study comparing cabazitaxel/prednisone to cabazitaxel alone for second-line chemotherapy in men with metastatic castrate resistant prostate cancer (mCRPC): CABACARE

Annals of Oncology ◽

10.1093/annonc/mdx370.058 ◽

2017 ◽

Vol 28 ◽

pp. v292-v293 ◽

Cited By ~ 1

Author(s):

C. Buonerba ◽

D. Bosso ◽

S. De Placido ◽

G. Di Lorenzo

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Second Line ◽

Randomized Phase Ii ◽

Castrate Resistant Prostate Cancer ◽

Castrate Resistant ◽